ProCE Banner Activity

T-Cell Therapy Plus Avelumab: A New Approach in Merkel Cell Carcinoma

Clinical Thought
With avelumab now approved for MCC, what treatment options are available to patients not responding to checkpoint inhibitors? Read my thoughts on a promising new approach.

Released: August 09, 2017

Expiration: August 08, 2018

No longer available for credit.

Share

Faculty

Paul Nghiem

Paul Nghiem, MD

Professor and Head
Division of Dermatology
Department of Medicine
University of Washington
Seattle, Washington

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by an educational grant from

Merck KGaA

Pfizer, Inc.

Faculty Disclosure

Primary Author

Paul Nghiem, MD

Professor and Head
Division of Dermatology
Department of Medicine
University of Washington
Seattle, Washington

Paul Nghiem, MD, has disclosed that he has received consulting fees from EMD Serono and funds for research support from Bristol-Myers Squibb.